Notice to Long-Term Shareholders of MicroStrategy, Inc. ( NASDAQ: MSTR ) ; Manhattan Associates, Inc. ( NASDAQ: MANH ) ; Napco Security Technologies, Inc. ( NASDAQ: NSSC ) ; and Treace Medical Concepts, Inc. ( NASDAQ: TMCI ) : Grabar Law Office is Investigating Claims on Your Behalf - Strategy ( NASDAQ:MSTR ) , Manhattan Associates ( NASDAQ:MANH )
PHILADELPHIA, June 27, 2025 ( GLOBE NEWSWIRE ) -- If you are a current MicroStrategy, Inc. MSTR shareholder who purchased MicroStrategy shares prior to April 30, 2024, you can seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to ...
Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs - Novo Nordisk ( NYSE:NVO )
U.K. MHRA and Genomics England will study genetic links to GLP-1-linked pancreatitis. Novo Nordisk offers $299 Wegovy deal from July 1-31, then raises price to $499 monthly. Get ahead of Wall Street reactions-Benzinga Pro delivers signals, squawk, and news fast. Now 60% off this 4th of July.
Rocket Pharmaceuticals, Inc. ( RCKT ) Securities Fraud Class Action Lawsuit Pending: Contact Wolf Haldenstein Before August 11, 2025 to Discuss Your Rights - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, June 27, 2025 ( GLOBE NEWSWIRE ) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all investors who purchased or otherwise acquired securities of Rocket Pharmaceuticals, Inc.
Class Action Announcement for Hims & Hers Health, Inc. ( HIMS ) : Kessler Topaz Meltzer & Check, LLP - Hims & Hers Health ( NYSE:HIMS )
RADNOR, Pa., June 27, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, ...
B. Riley Farber and GlassRatner Acquired by Toronto-Based TorQuest Partners
Toronto, Canada, June 27, 2025 ( GLOBE NEWSWIRE ) -- B. Riley Farber Advisory Inc. ( "B. Riley Farber" ) and GlassRatner Advisory & Capital Group, LLC ( "GlassRatner" ) , leading providers of high-value financial advisory services, are pleased to announce their acquisition by Toronto-based ...
Immerse Yourself Now,' Says Google DeepMind's Demis Hassabis - Why Gen Alpha Must Become AI 'Ninjas' Before It's Too Late - Microsoft ( NASDAQ:MSFT ) , Alphabet ( NASDAQ:GOOG )
"Immerse yourself now in AI tools," said Google DeepMind Chief Executive Officer Demis Hassabis on the May 23 "Hard Fork" podcast. His warning to Gen Alpha came as generative AI writes code, mixes music, and even drafts medical briefs. "Kids who master these tools early will ride the next wave," ...
GlassRatner Acquired by TorQuest Partners, Reestablishes Itself as an Independent Brand
Atlanta, GA, June 27, 2025 ( GLOBE NEWSWIRE ) -- GlassRatner Advisory & Capital Group, LLC ( "GlassRatner" ) , a leading provider of specialty professional and advisory services has reestablished itself as an independent brand following its acquisition by TorQuest Partners from B.
Michael Saylor Says Bitcoin Treasury Companies Can Unlock Even More Growth: Here's How
Michael Saylor says Bitcoin treasury companies should expand into credit markets to drive broader BTC adoption. Strategy's Strike and Strife are pioneering examples, targeting retail investors and retirees with Bitcoin-collateralized returns.
The Mindful Lemon Selects Qualifacts to Support Rapid Expansion and Enhance Client Care in LA County and Beyond
Nashville, Tenn. & Santa Clarita, Cali., June 27, 2025 ( GLOBE NEWSWIRE ) -- Qualifacts, a leading provider of end-to-end electronic health record ( EHR ) software and data solutions designed specifically for behavioral health and human services organizations, proudly announces a new partnership ...
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
CAMBRIDGE, Mass., June 27, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy ( SMA ) .












